Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review
Crossref DOI link: https://doi.org/10.1007/s40121-022-00609-9
Published Online: 2022-03-31
Published Print: 2022-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Marshall, Gary S.
Fergie, Jaime
Presa, Jessica
Peyrani, Paula
Funding for this research was provided by:
Pfizer
Text and Data Mining valid from 2022-03-31
Version of Record valid from 2022-03-31
Article History
Received: 15 September 2021
Accepted: 14 February 2022
First Online: 31 March 2022